<DOC>
	<DOCNO>NCT01705236</DOCNO>
	<brief_summary>This 3-year , prospective , multi-center , open-label study describe long term change optical coherence tomography ( OCT ) parameter RRMS patient treatment Fingolimod . It design longitudinally study degeneration retinal axon measure change RNFL thickness late OCT-technology . Correlations OCT finding available MRI data clinical finding may enhance understand relationship CNS inflammation , tissue injury , regeneration neurological deficit context fingolimod therapy .</brief_summary>
	<brief_title>A 3-year Multi-center Study Describe Changes OCT Parameters Under Treatment With GilenyaÂ®</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Inclusion Criteria Patients eligible inclusion study fulfill follow criterion : 1 . Written informed consent must obtain assessment perform . 2 . Male female subject age 1865 year . 3 . Subjects relapse remit MS define 2010 revise McDonald criterion ( see Appendix 4 ) . 4 . Patients Expanded Disability Status Scale ( EDSS ) score 06.0 inclusive ( see Appendix 6 ) . 5 . Patients stable immunomodulatory treatment fingolimod least 1 month 4 month prior screen accord local label 6 . Neurologically stable evidence relapse within 30 day prior inclusion date 7 . Sufficient ability read , write , communicate understand Exclusion Criteria Patients fulfil follow criterion eligible inclusion study : 1 . Patients treat : systemic corticosteroid immunoglobulin within 1 month prior screen ; immunosuppressive medication azathioprine , cyclophosphamide , methotrexate within 3 month prior screen ; monoclonal antibody ( include natalizumab ) within 3 month prior screen ; mitoxantrone within 6 month prior screen cladribine time . 2 . Patients medically unstable condition , assess primary treat physician site . 3 . Patients follow cardiovascular condition : history myocardial infarction current unstable ischemic heart disease ; Heart failure ( NYHA IIIIV ) severe cardiac disease determine Investigator ( see Appendix 5 ) ; history presence seconddegree AV block , Type II thirddegree AV block patient receive Class Ia ( ajmaline , disopyramide , procainamide , quinidine ) III antiarrhythmic drug ( e.g. , amiodarone , bretylium , sotalol , ibulitide , azimilide , dofelitide ) ; prove history sick sinus syndrome ; uncontrolled hypertension 4 . Patients severe respiratory disease , pulmonary fibrosis , chronic obstructive pulmonary disease ( Class IIIIV ) . 5 . Patients history specific MRI finding ( tumor , subdural haematoma , postcontusional change , territorial stroke , neurodegenerative disorder , aneurysm/arteriovenous malformation , evidence past macroscopic haemorrhage , relevant MRI finding would interfere evaluation ) 6 . Any severe disability clinical impairment prevent patient meet study requirement investigator ` discretion 7 . History malignancy organ system , treat untreated , within past 5 year whether evidence local recurrence metastasis , exception localize basal cell carcinoma skin 8 . Patients receive investigational drug ( exclude fingolimod ) therapy within 90 day 5 halflives screen , whichever longer . 9 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG test ( serum ) 10 . Patients ophthalmologic reason RNFL pathology MS , : optic neuropathy , active advanced glaucoma , injury optic nerve base ophthalmologist 's clinical judgment 11. history presence severe myopia 1. patient refractive surgery , refractive error great 6.00 diopter 2. pathologic fundus change high myopia , retinal pigmentary atrophy , besides peripapillary atrophy ( atrophy involve macula ) staphyloma 3. patient previous refractive surgery , axial eye length great 26 mm 12 . Acute optic neuritis within past 6 month screen 13 . Evidence advance , nonproliferative proliferative diabetic retinopathy 14 . Presence retinal condition associate edema , subretinal fluid , cyst , etc . 15 . Concomitant use drug may directly affect retinal structure function ( e.g . chronic systemic corticosteroid [ &gt; 30 consecutive day ; dose high Cushing threshold e.g . prednisone 7.5mg/d ] , intraocular antiangiogenic drug [ ranibizumab , bevacizumab ] , intraocular steroid etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>